The role of the IL-22/IL-22R1 axis in cancer

Cytokine and Growth Factor Reviews

Volumn 25, Issue 3, 2014, Pages 257-271

  Lim, Chrissie ^a   Savan, Ram ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Cancer; IL 22R1; Inflammation; Interleukin 22; STAT3

Indexed keywords

FEZAKINUMAB; GAMMA INTERFERON; ILV O094; INTERLEUKIN 20; INTERLEUKIN 22; INTERLEUKIN 24; NEUTRALIZING ANTIBODY; STAT1 PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN; UNCLASSIFIED DRUG; IL21R PROTEIN, HUMAN; INTERLEUKIN 21 RECEPTOR ALPHA; INTERLEUKIN DERIVATIVE; INTERLEUKIN-22;

ANTIVIRAL ACTIVITY; APOPTOSIS; BINDING AFFINITY; BRAIN CANCER; CANCER GROWTH; CARCINOGENESIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CELL SURVIVAL; COLORECTAL CANCER; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; DIGESTIVE SYSTEM CANCER; DRUG EFFICACY; DRUG RESPONSE; DRUG TARGETING; EPITHELIAL MESENCHYMAL TRANSITION; GENETIC VARIABILITY; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; LIVER CELL CARCINOMA; LIVER FIBROSIS; LIVER INJURY; LIVER PROTECTION; LUNG CANCER; LYMPHOCYTE DIFFERENTIATION; MACROPHAGE; METASTASIS; NONHUMAN; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SKIN CANCER; TH17 CELL; TISSUE REGENERATION; TUMOR INVASION; TUMOR MICROENVIRONMENT; ANIMAL; CELL TRANSFORMATION; IMMUNOLOGY; NEOPLASM; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; INTERLEUKIN-21 RECEPTOR ALPHA SUBUNIT; INTERLEUKINS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84902077790     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2014.04.005     Document Type: Review

References (250)

1. Dumoutier L., Louahed J., Renauld J.C. Cloning and characterization of IL-10-related T cell-derived inducible factor (IL-TIF), a novel cytokine structurally related to IL-10 and inducible by IL-9. J Immunol 2000, 164:1814-1819.
2. Xie M.H., Aggarwal S., Ho W.H., Foster J., Zhang Z.M., Stinson J., et al. Interleukin (IL)-22, a novel human cytokine that signals through the interferon receptor-related proteins CRF2-4 and IL-22R. J Biol Chem 2000, 275:31335-31339.
3. Dumoutier L., Van Roost E., Colau D., Renauld J.C. Human interleukin-10-related T cell-derived inducible factor: molecular cloning and functional characterization as an hepatocyte-stimulating factor. Proc Natl Acad Sci U S A 2000, 97:10144-10149.
4. Nagem R.A.P., Colau D., Dumoutier L., Renauld J.C., Ogata C., Polikarpov I. Crystal structure of recombinant human interleukin-22. Structure 2002, 10:1051-1062.
5. Ouyang W., Rutz S., Crellin N.K., Valdez P.A., Hymowitz S.G. Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu Rev Immunol 2011, 29:71-109.
6. Dumoutier L., Van Roost E., Ameye G., Michaux L., Renauld J.C. IL-TIF/IL-22: genomic organization and mapping of the human and mouse genes. Genes Immun 2000, 1:488-494.
7. Igawa D., Sakai M., Savan R. An unexpected discovery of two interferon gamma-like genes along with interleukin (IL)-22 and -26 from teleost: IL-22 and -26 genes have been described for the first time outside mammals. Mol Immunol 2006, 43:999-1009.
8. Kotenko S.V., Izotova L.S., Mirochnitchenko O.V., Esterova E., Dickensheets H., Donnelly R.P., et al. Identification of the functional interleukin-22 (IL-22) receptor complex - the IL-10R2 chain (IL-10R beta) is a common chain of both the IL-10 and IL-22 (IL-10-related T cell-derived inducible factor, IL-TIF) receptor complexes. J Biol Chem 2001, 276:2725-2732.
9. Brand S., Dambacher J., Beigel F., Zitzmann K., Heeg M.H., Weiss T.S., et al. IL-22-mediated liver cell regeneration is abrogated by SOCS-1/3 overexpression in vitro. Am J Physiol Gastrointest Liver Physiol 2007, 292:G1019-G1028.
10. Sabat R., Ouyang W., Wolk K. Therapeutic opportunities of the IL-22-IL-22R1 system. Nat Rev Drug Discov 2013, 13:21-38.
11. Sanos S.L., Bui V.L., Mortha A., Oberle K., Heners C., Johner C., et al. RORgammat and commensal microflora are required for the differentiation of mucosal interleukin 22-producing NKp46+ cells. Nat Immunol 2009, 10:83-91.
12. Takatori H., Kanno Y., Watford W.T., Tato C.M., Weiss G., Ivanov I.I., et al. Lymphoid tissue inducer-like cells are an innate source of IL-17 and IL-22. J Exp Med 2009, 206:35-41.
13. Goto M., Murakawa M., Kadoshima-Yamaoka K., Tanaka Y., Nagahira K., Fukuda Y., et al. Murine NKT cells produce Th17 cytokine interleukin-22. Cell Immunol 2009, 254:81-84.
14. Lecart S., Morel F., Noraz N., Pene J., Garcia M., Boniface K., et al. IL-22, in contrast to IL-10, does not induce Ig production, due to absence of a functional IL-22 receptor on activated human B cells. Int Immunol 2002, 14:1351-1356.
15. Whittington H.A., Armstrong L., Uppington K.M., Millar A.B. Interleukin-22: a potential immunomodulatory molecule in the lung. Am J Respir Cell Mol Biol 2004, 31:220-226.
16. Wolk K., Kunz S., Witte E., Friedrich M., Asadullah K., Sabat R. IL-22 increases the innate immunity of tissues. Immunity 2004, 21:241-254.
17. Boniface K., Bernard F.X., Garcia M., Gurney A.L., Lecron J.C., Morel F. IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes. J Immunol 2005, 174:3695-3702.
18. Radaeva S., Sun R., Pan H.N., Hong F. Gao B. Interleukin 22 (IL-22) plays a protective role in T cell-mediated murine hepatitis: IL-22 is a survival factor for hepatocytes via STAT3 activation. Hepatology 2004, 39:1332-1342.
19. Wolk K., Witte E., Wallace E., Docke W.D., Kunz S., Asadullah K., et al. IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol 2006, 36:1309-1323.
20. Nagalakshmi M.L., Rascle A., Zurawski S., Menon S., de Waal Malefyt R. Interleukin-22 activates STAT3 and induces IL-10 by colon epithelial cells. Int Immunopharmacol 2004, 4:679-691.
21. Aggarwal S., Xie M.H., Maruoka M., Foster J., Gurney A.L. Acinar cells of the pancreas are a target of interleukin-22. J Interferon Cytokine Res 2001, 21:1047-1053.
22. Shioya M., Andoh A., Kakinoki S., Nishida A., Fujiyama Y. Interleukin 22 receptor 1 expression in pancreas islets. Pancreas 2008, 36:197-199.
23. Kong X., Feng D., Wang H., Hong F., Bertola A., Wang F.S., et al. Interleukin-22 induces hepatic stellate cell senescence and restricts liver fibrosis in mice. Hepatology 2012, 56:1150-1159.
24. Andoh A., Zhang Z., Inatomi O., Fujino S., Deguchi Y., Araki Y., et al. Interleukin-22, a member of the IL-10 subfamily, induces inflammatory responses in colonic subepithelial myofibroblasts. Gastroenterology 2005, 129:969-984.
25. Chang Y., Al-Alwan L., Risse P.A., Halayko A.J., Martin J.G., Baglole C.J., et al. Th17-associated cytokines promote human airway smooth muscle cell proliferation. FASEB J 2012, 26:5152-5160.
26. Dudakov J.A., Hanash A.M., Jenq R.R., Young L.F., Ghosh A., Singer N.V., et al. Interleukin-22 drives endogenous thymic regeneration in mice. Science 2012, 336:91-95.
27. Yu H., Pardoll D., Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009, 9:798-809.
28. Rutz S., Eidenschenk C., Ouyang W. IL-22, not simply a Th17 cytokine. Immunol Rev 2013, 252:116-132.
29. Sonnenberg G.F., Fouser L.A., Artis D. Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22. Nat Immunol 2011, 12:383-390.
30. Gurney A.L. IL-22, a Th1 cytokine that targets the pancreas and select other peripheral tissues. Int Immunopharmacol 2004, 4:669-677.
31. Eyerich S., Eyerich K., Pennino D., Carbone T., Nasorri F., Pallotta S., et al. Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J Clin Invest 2009, 119:3573-3585.
32. Duhen T., Geiger R., Jarrossay D., Lanzavecchia A., Sallusto F. Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat Immunol 2009, 10:857-863.
33. Volpe E., Touzot M., Servant N., Marloie-Provost M.A., Hupe P., Barillot E., et al. Multiparametric analysis of cytokine-driven human Th17 differentiation reveals a differential regulation of IL-17 and IL-22 production. Blood 2009, 114:3610-3614.
34. Zheng Y., Danilenko D.M., Valdez P., Kasman I., Eastham-Anderson J., Wu J., et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007, 445:648-651.
35. Ivanov I.I., McKenzie B.S., Zhou L., Tadokoro C.E., Lepelley A., Lafaille J.J., et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 2006, 126:1121-1133.
36. Zhou L., Ivanov I.I., Spolski R., Min R., Shenderov K., Egawa T., et al. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol 2007, 8:967-974.
37. Yang X.O., Pappu B.P., Nurieva R., Akimzhanov A., Kang H.S., Chung Y., et al. T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma. Immunity 2008, 28:29-39.
38. Ciofani M., Madar A., Galan C., Sellars M., Mace K., Pauli F., et al. A validated regulatory network for Th17 cell specification. Cell 2012, 151:289-303.
39. Mathur A.N., Chang H.C., Zisoulis D.G., Stritesky G.L., Yu Q., O'Malley J.T., et al. Stat3 and Stat4 direct development of IL-17-secreting Th cells. J Immunol 2007, 178:4901-4907.
40. Durant L., Watford W.T., Ramos H.L., Laurence A., Vahedi G., Wei L., et al. Diverse targets of the transcription factor STAT3 contribute to T cell pathogenicity and homeostasis. Immunity 2010, 32:605-615.
41. Chung Y., Chang S.H., Martinez G.J., Yang X.O., Nurieva R., Kang H.S., et al. Critical regulation of early Th17 cell differentiation by interleukin-1 signaling. Immunity 2009, 30:576-587.
42. Nurieva R., Yang X.O., Martinez G., Zhang Y., Panopoulos A.D., Ma L., et al. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature 2007, 448:480-483.
43. Bettelli E., Carrier Y., Gao W., Korn T., Strom T.B., Oukka M., et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006, 441:235-238.
44. Ghoreschi K., Laurence A., Yang X.P., Tato C.M., McGeachy M.J., Konkel J.E., et al. Generation of pathogenic T(H)17 cells in the absence of TGF-beta signalling. Nature 2010, 467:967-971.
45. Palmer M.T., Lee Y.K., Maynard C.L., Oliver J.R., Bikle D.D., Jetten A.M., et al. Lineage-specific effects of 1,25-dihydroxyvitamin D(3) on the development of effector CD4 T cells. J Biol Chem 2011, 286:997-1004.
46. Elias K.M., Laurence A., Davidson T.S., Stephens G., Kanno Y., Shevach E.M., et al. Retinoic acid inhibits Th17 polarization and enhances FoxP3 expression through a Stat-3/Stat-5 independent signaling pathway. Blood 2008, 111:1013-1020.
47. Annunziato F., Cosmi L., Santarlasci V., Maggi L., Liotta F., Mazzinghi B., et al. Phenotypic and functional features of human Th17 cells. J Exp Med 2007, 204:1849-1861.
48. Singh S.P., Zhang H.H., Foley J.F., Hedrick M.N., Farber J.M. Human T cells that are able to produce IL-17 express the chemokine receptor CCR6. J Immunol 2008, 180:214-221.
49. Hemdan N.Y. Anti-cancer versus cancer-promoting effects of the interleukin-17-producing T helper cells. Immunol Lett 2013, 149:123-133.
50. Ye J., Livergood R.S., Peng G. The role and regulation of human Th17 cells in tumor immunity. Am J Pathol 2013, 182:10-20.
51. Martin F., Apetoh L., Ghiringhelli F. Controversies on the role of Th17 in cancer: a TGF-beta-dependent immunosuppressive activity. Trends Mol Med 2012, 18:742-749.
52. Yen H.R., Harris T.J., Wada S., Grosso J.F., Getnet D., Goldberg M.V., et al. Tc17 CD8 T cells: functional plasticity and subset diversity. J Immunol 2009, 183:7161-7168.
53. + T cells. J Immunol 2009, 182:5296-5305.
54. + T cells producing IL-17. J Immunol 2009, 182:1794-1798.
55. Huber M., Heink S., Grothe H., Guralnik A., Reinhard K., Elflein K., et al. A Th17-like developmental process leads to CD8(+) Tc17 cells with reduced cytotoxic activity. Eur J Immunol 2009, 39:1716-1725.
56. Hamada H., Garcia-Hernandez Mde L., Reome J.B., Misra S.K., Strutt T.M., McKinstry K.K., et al. Tc17, a unique subset of CD8 T cells that can protect against lethal influenza challenge. J Immunol 2009, 182:3469-3481.
57. + T lymphocytes from psoriasis skin plaques are cytotoxic effector cells that secrete Th17-related cytokines. J Leukoc Biol 2009, 86:435-443.
58. Trifari S., Kaplan C.D., Tran E.H., Crellin N.K., Spits H. Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells. Nat Immunol 2009, 10:864-871.
59. Liu Y., Yang B., Ma J., Wang H., Huang F., Zhang J., et al. Interleukin-21 induces the differentiation of human Tc22 cells via phosphorylation of signal transducers and activators of transcription. Immunology 2011, 132:540-548.
60. Vantourout P., Hayday A. Six-of-the-best: unique contributions of gammadelta T cells to immunology. Nat Rev Immunol 2013, 13:88-100.
61. Martin B., Hirota K., Cua D.J., Stockinger B., Veldhoen M. Interleukin-17-producing gammadelta T cells selectively expand in response to pathogen products and environmental signals. Immunity 2009, 31:321-330.
62. Sutton C.E., Lalor S.J., Sweeney C.M., Brereton C.F., Lavelle E.C., Mills K.H. Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity. Immunity 2009, 31:331-341.
63. Serriari N.E., Eoche M., Lamotte L., Fumery M., Marcelo P., Chatelain D., et al. Innate Mucosal-Associated Invariant T (MAIT) cells are activated in Inflammatory Bowel Diseases. Clin Exp Immunol 2014, 176(2):266-274.
64. Leeansyah E., Loh L., Nixon D.F., Sandberg J.K. Acquisition of innate-like microbial reactivity in mucosal tissues during human fetal MAIT-cell development. Nat Commun 2014, 5:3143.
65. Cella M., Fuchs A., Vermi W., Facchetti F., Otero K., Lennerz J.K., et al. A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity. Nature 2009, 457:722-725.
66. Lee J.S., Cella M., McDonald K.G., Garlanda C., Kennedy G.D., Nukaya M., et al. AHR drives the development of gut ILC22 cells and postnatal lymphoid tissues via pathways dependent on and independent of Notch. Nat Immunol 2012, 13:144-151.
67. Doisne J.M., Soulard V., Becourt C., Amniai L., Henrot P., Havenar-Daughton C., et al. Cutting edge: crucial role of IL-1 and IL-23 in the innate IL-17 response of peripheral lymph node NK1.1-invariant NKT cells to bacteria. J Immunol 2011, 186:662-666.
68. Crellin N.K., Trifari S., Kaplan C.D., Cupedo T., Spits H. Human NKp44+IL-22+ cells and LTi-like cells constitute a stable RORC+ lineage distinct from conventional natural killer cells. J Exp Med 2010, 207:281-290.
69. Satoh-Takayama N., Vosshenrich C.A., Lesjean-Pottier S., Sawa S., Lochner M., Rattis F., et al. Microbial flora drives interleukin 22 production in intestinal NKp46+ cells that provide innate mucosal immune defense. Immunity 2008, 29:958-970.
70. Luci C., Reynders A., Ivanov I.I., Cognet C., Chiche L., Chasson L., et al. Influence of the transcription factor RORgammat on the development of NKp46+ cell populations in gut and skin. Nat Immunol 2009, 10:75-82.
71. Eberl G., Marmon S., Sunshine M.J., Rennert P.D., Choi Y., Littman D.R. An essential function for the nuclear receptor RORgamma(t) in the generation of fetal lymphoid tissue inducer cells. Nat Immunol 2004, 5:64-73.
72. Zheng Y., Valdez P.A., Danilenko D.M., Hu Y., Sa S.M., Gong Q., et al. Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. Nat Med 2008, 14:282-289.
73. Pickert G., Neufert C., Leppkes M., Zheng Y., Wittkopf N., Warntjen M., et al. STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing. J Exp Med 2009, 206:1465-1472.
74. Kulkarni O.P., Hartter I., Mulay S.R., Hagemann J., Darisipudi M.N., Kumar Vr.S., et al. Toll-like receptor 4-induced IL-22 accelerates kidney regeneration. J Am Soc Nephrol 2014, 25(5):978-989.
75. Jiang R., Tan Z., Deng L., Chen Y., Xia Y., Gao Y., et al. Interleukin-22 promotes human hepatocellular carcinoma by activation of STAT3. Hepatology 2011, 54:900-909.
76. Zindl C.L., Lai J.F., Lee Y.K., Maynard C.L., Harbour S.N., Ouyang W., et al. IL-22-producing neutrophils contribute to antimicrobial defense and restitution of colonic epithelial integrity during colitis. Proc Natl Acad Sci U S A 2013, 110:12768-12773.
77. Nagalakshmi M.L., Murphy E., McClanahan T., de Waal Malefyt R. Expression patterns of IL-10 ligand and receptor gene families provide leads for biological characterization. Int Immunopharmacol 2004, 4:577-592.
78. Mielke L.A., Jones S.A., Raverdeau M., Higgs R., Stefanska A., Groom J.R., et al. Retinoic acid expression associates with enhanced IL-22 production by gammadelta T cells and innate lymphoid cells and attenuation of intestinal inflammation. J Exp Med 2013, 210:1117-1124.
79. Kirchberger S., Royston D.J., Boulard O., Thornton E., Franchini F., Szabady R.L., et al. Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse model. J Exp Med 2013, 210:917-931.
80. Mizoguchi A. Healing of intestinal inflammation by IL-22. Inflamm Bowel Dis 2012, 18:1777-1784.
81. Kreymborg K., Etzensperger R., Dumoutier L., Haak S., Rebollo A., Buch T., et al. IL-22 is expressed by Th17 cells in an IL-23-dependent fashion, but not required for the development of autoimmune encephalomyelitis. J Immunol 2007, 179:8098-8104.
82. Kimura A., Naka T., Nohara K., Fujii-Kuriyama Y., Kishimoto T. Aryl hydrocarbon receptor regulates Stat1 activation and participates in the development of Th17 cells. Proc Natl Acad Sci U S A 2008, 105:9721-9726.
83. Ramirez J.M., Brembilla N.C., Sorg O., Chicheportiche R., Matthes T., Dayer J.M., et al. Activation of the aryl hydrocarbon receptor reveals distinct requirements for IL-22 and IL-17 production by human T helper cells. Eur J Immunol 2010, 40:2450-2459.
84. Veldhoen M., Hirota K., Christensen J., O'Garra A., Stockinger B. Natural agonists for aryl hydrocarbon receptor in culture medium are essential for optimal differentiation of Th17 T cells. J Exp Med 2009, 206:43-49.
85. + T cells by stimulating the aryl hydrocarbon receptor. Proc Natl Acad Sci U S A 2010, 107:5943-5948.
86. Murano T., Okamoto R., Ito G., Nakata T., Hibiya S., Shimizu H., et al. Hes1 promotes the IL-22-mediated antimicrobial response by enhancing STAT3-dependent transcription in human intestinal epithelial cells. Biochem Biophys Res Commun 2014, 443(3):840-846.
87. Rutz S., Noubade R., Eidenschenk C., Ota N., Zeng W., Zheng Y., et al. Transcription factor c-Maf mediates the TGF-beta-dependent suppression of IL-22 production in T(H)17 cells. Nat Immunol 2011, 12:1238-1245.
88. Rudloff I., Bachmann M., Pfeilschifter J., Muhl H. Mechanisms of rapid induction of interleukin-22 in activated T cells and its modulation by cyclosporin a. J Biol Chem 2012, 287:4531-4543.
89. Wan Q., Kozhaya L., ElHed A., Ramesh R., Carlson T.J., Djuretic I.M., et al. Cytokine signals through PI-3 kinase pathway modulate Th17 cytokine production by CCR6+ human memory T cells. J Exp Med 2011, 208:1875-1887.
90. Molinero L.L., Cubre A., Mora-Solano C., Wang Y., Alegre M.L. T cell receptor/CARMA1/NF-kappaB signaling controls T-helper (Th) 17 differentiation. Proc Natl Acad Sci U S A 2012, 109:18529-18534.
91. Hansson M., Silverpil E., Linden A., Glader P. Interleukin-22 produced by alveolar macrophages during activation of the innate immune response. Inflamm Res 2013, 62:561-569.
92. Baird A.M., Gray S.G., O'Byrne K.J. IL-20 is epigenetically regulated in NSCLC and down regulates the expression of VEGF. Eur J Cancer 2011, 47:1908-1918.
93. Tohyama M., Hanakawa Y., Shirakata Y., Dai X., Yang L., Hirakawa S., et al. IL-17 and IL-22 mediate IL-20 subfamily cytokine production in cultured keratinocytes via increased IL-22 receptor expression. Eur J Immunol 2009, 39:2779-2788.
94. Su L., Liao Q., Wu Y., Chen X. Kaposi's sarcoma-associated herpesvirus-encoded LANA down-regulates IL-22R1 expression through a cis-acting element within the promoter region. PLoS ONE 2011, 6:e19106.
95. Gelebart P., Zak Z., Dien-Bard J., Anand M., Lai R. Interleukin 22 signaling promotes cell growth in mantle cell lymphoma. Transl Oncol 2011, 4:9-19.
96. + anaplastic large cell lymphoma. Leukemia 2008, 22:1595-1603.
97. Savan R., McFarland A.P., Reynolds D.A., Feigenbaum L., Ramakrishnan K., Karwan M., et al. A novel role for IL-22R1 as a driver of inflammation. Blood 2011, 117:575-584.
98. Ito M., Teshima K., Ikeda S., Kitadate A., Watanabe A., Nara M., et al. MicroRNA-150 inhibits tumor invasion and metastasis by targeting the chemokine receptor CCR6 in advanced cutaneous T-cell lymphoma. Blood 2014, 123(10):1499-1511.
99. Dumoutier L., Lejeune D., Colau D., Renauld J.C. Cloning and characterization of IL-22 binding protein, a natural antagonist of IL-10-related T cell-derived inducible factor/IL-22. J Immunol 2001, 166:7090-7095.
100. Xu W., Presnell S.R., Parrish-Novak J., Kindsvogel W., Jaspers S., Chen Z., et al. A soluble class II cytokine receptor, IL-22RA2, is a naturally occurring IL-22 antagonist. Proc Natl Acad Sci U S A 2001, 98:9511-9516.
101. Kotenko S.V., Izotova L.S., Mirochnitchenko O.V., Esterova E., Dickensheets H., Donnelly R.P., et al. Identification, cloning, and characterization of a novel soluble receptor that binds IL-22 and neutralizes its activity. J Immunol 2001, 166:7096-7103.
102. Weiss B., Wolk K., Grunberg B.H., Volk H.D., Sterry W., Asadullah K., et al. Cloning of murine IL-22 receptor alpha 2 and comparison with its human counterpart. Genes Immun 2004, 5:330-336.
103. Wei C.C., Ho T.W., Liang W.G., Chen G.Y., Chang M.S. Cloning and characterization of mouse IL-22 binding protein. Genes Immun 2003, 4:204-211.
104. Dumoutier L., Leemans C., Lejeune D., Kotenko S.V., Renauld J.C. Cutting edge: STAT activation by IL-19, IL-20 and mda-7 through IL-20 receptor complexes of two types. J Immunol 2001, 167:3545-3549.
105. Jones B.C., Logsdon N.J., Walter M.R. Structure of IL-22 bound to its high-affinity IL-22R1 chain. Structure 2008, 16:1333-1344.
106. de Moura P.R., Watanabe L., Bleicher L., Colau D., Dumoutier L., Lemaire M.M., et al. Crystal structure of a soluble decoy receptor IL-22BP bound to interleukin-22. FEBS Lett 2009, 583:1072-1077.
107. Huber S., Gagliani N., Zenewicz L.A., Huber F.J., Bosurgi L., Hu B., et al. IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine. Nature 2012, 491:259-263.
108. Martin J.C., Beriou G., Heslan M., Chauvin C., Utriainen L., Aumeunier A., et al. Interleukin-22 binding protein (IL-22BP) is constitutively expressed by a subset of conventional dendritic cells and is strongly induced by retinoic acid. Mucosal Immunol 2014, 7:101-113.
109. Wolk K., Witte E., Hoffmann U., Doecke W.D., Endesfelder S., Asadullah K., et al. IL-22 induces lipopolysaccharide-binding protein in hepatocytes: a potential systemic role of IL-22 in Crohn's disease. J Immunol 2007, 178:5973-5981.
110. Wade R., Di Bernardo M.C., Richards S., Rossi D., Crowther-Swanepoel D., Gaidano G., et al. Association between single nucleotide polymorphism-genotype and outcome of patients with chronic lymphocytic leukemia in a randomized chemotherapy trial. Haematologica 2011, 96:1496-1503.
111. Beyeen A.D., Adzemovic M.Z., Ockinger J., Stridh P., Becanovic K., Laaksonen H., et al. IL-22RA2 associates with multiple sclerosis and macrophage effector mechanisms in experimental neuroinflammation. J Immunol 2010, 185:6883-6890.
112. Reimann E., Kingo K., Karelson M., Reemann P., Loite U., Sulakatko H., et al. The mRNA expression profile of cytokines connected to the regulation of melanocyte functioning in vitiligo skin biopsy samples and peripheral blood mononuclear cells. Hum Immunol 2012, 73:393-398.
113. Sugimoto K., Ogawa A., Mizoguchi E., Shimomura Y., Andoh A., Bhan A.K., et al. IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. J Clin Invest 2008, 118:534-544.
114. Lejeune D., Dumoutier L., Constantinescu S., Kruijer W., Schuringa J.J., Renauld J.C. Interleukin-22 (IL-22) activates the JAK/STAT, ERK, JNK, and p38 MAP kinase pathways in a rat hepatoma cell line. Pathways that are shared with and distinct from IL-10. J Biol Chem 2002, 277:33676-33682.
115. Bournazou E., Bromberg J. Targeting the tumor microenvironment: JAK-STAT3 signaling. JAKSTAT 2013, 2:e23828.
116. Bromberg J., Wang T.C. Inflammation and cancer: IL-6 and STAT3 complete the link. Cancer Cell 2009, 15:79-80.
117. Grivennikov S.I., Karin M. Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev 2010, 21:11-19.
118. Dumoutier L., de Meester C., Tavernier J., Renauld J.C. New activation modus of STAT3: a tyrosine-less region of the interleukin-22 receptor recruits STAT3 by interacting with its coiled-coil domain. J Biol Chem 2009, 284:26377-26384.
119. Meng S., Gui Q., Xu Q., Lu K., Jiao X., Fan J., et al. Association of Shp2 with phosphorylated IL-22R1 is required for interleukin-22-induced MAP kinase activation. J Mol Cell Biol 2010, 2:223-230.
120. Zhang F., Shang D., Zhang Y., Tian Y. Interleukin-22 suppresses the growth of A498 renal cell carcinoma cells via regulation of STAT1 pathway. PLoS ONE 2011, 6:e20382.
121. Bachmann M., Ulziibat S., Hardle L., Pfeilschifter J., Muhl H. IFNalpha converts IL-22 into a cytokine efficiently activating STAT1 and its downstream targets. Biochem Pharmacol 2013, 85:396-403.
122. Ziesche E., Bachmann M., Kleinert H., Pfeilschifter J., Muhl H. The interleukin-22/STAT3 pathway potentiates expression of inducible nitric-oxide synthase in human colon carcinoma cells. J Biol Chem 2007, 282:16006-16015.
123. Brand S., Beigel F., Olszak T., Zitzmann K., Eichhorst S.T., Otte J.M., et al. IL-22 is increased in active Crohn's disease and promotes proinflammatory gene expression and intestinal epithelial cell migration. Am J Physiol Gastrointest Liver Physiol 2006, 290:G827-G838.
124. Xu M.J., Feng D., Wang H., Guan Y., Yan X., Gao B. IL-22 ameliorates renal ischemia-reperfusion injury by targeting proximal tubule epithelium. J Am Soc Nephrol 2014, 25(5):967-977.
125. Zhang W., Dang E., Shi X., Jin L., Feng Z., Hu L., et al. The pro-inflammatory cytokine IL-22 up-regulates keratin 17 expression in keratinocytes via STAT3 and ERK1/2. PLoS ONE 2012, 7:e40797.
126. Ren X., Hu B., Colletti L.M. IL-22 is involved in liver regeneration after hepatectomy. Am J Physiol Gastrointest Liver Physiol 2010, 298:G74-G80.
127. Weber G.F., Gaertner F.C., Erl W., Janssen K.P., Blechert B., Holzmann B., et al. IL-22-mediated tumor growth reduction correlates with inhibition of ERK1/2 and AKT phosphorylation and induction of cell cycle arrest in the G2-M phase. J Immunol 2006, 177:8266-8272.
128. Mitra A., Raychaudhuri S.K., Raychaudhuri S.P. IL-22 induced cell proliferation is regulated by PI3K/Akt/mTOR signaling cascade. Cytokine 2012, 60:38-42.
129. Fukui H., Sekikawa A., Tanaka H., Fujimori Y., Katake Y., Fujii S., et al. DMBT1 is a novel gene induced by IL-22 in ulcerative colitis. Inflamm Bowel Dis 2011, 17:1177-1188.
130. Cho K.A., Kim J.Y., Woo S.Y., Park H.J., Lee K.H., Pae C.U. Interleukin-17, interleukin-22 induced proinflammatory cytokine production in keratinocytes via inhibitor of nuclear factor kappaB kinase-alpha expression. Ann Dermatol 2012, 24:398-405.
131. Sa S.M., Valdez P.A., Wu J., Jung K., Zhong F., Hall L., et al. The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis. J Immunol 2007, 178:2229-2240.
132. Nograles K.E., Zaba L.C., Guttman-Yassky E., Fuentes-Duculan J., Suarez-Farinas M., Cardinale I., et al. Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol 2008, 159:1092-1102.
133. Aujla S.J., Chan Y.R., Zheng M., Fei M., Askew D.J., Pociask D.A., et al. IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia. Nat Med 2008, 14:275-281.
134. Cho K.A., Suh J.W., Lee K.H., Kang J.L., Woo S.Y. IL-17, IL-22 enhance skin inflammation by stimulating the secretion of IL-1beta by keratinocytes via the ROS-NLRP3-caspase-1 pathway. Int Immunol 2012, 24:147-158.
135. Bansal G., Das D., Hsieh C.Y., Wang Y.H., Gilmore B.A., Wong C.M., et al. IL-22 activates oxidant signaling in pulmonary vascular smooth muscle cells. Cell Signal 2013, 25:2727-2733.
136. Guilloteau K., Paris I., Pedretti N., Boniface K., Juchaux F., Huguier V., et al. Skin inflammation induced by the synergistic action of IL-17A, IL-22, oncostatin M, IL-1{alpha}, and TNF-{alpha} recapitulates some features of psoriasis. J Immunol 2010, 184(9):5263-5270.
137. Liang S.C., Tan X.Y., Luxenberg D.P., Karim R., Dunussi-Joannopoulos K., Collins M., et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 2006, 203:2271-2279.
138. Pennino D., Bhavsar P.K., Effner R., Avitabile S., Venn P., Quaranta M., et al. IL-22 suppresses IFN-gamma-mediated lung inflammation in asthmatic patients. J Allergy Clin Immunol 2013, 131:562-570.
139. Sonnenberg G.F., Nair M.G., Kirn T.J., Zaph C., Fouser L.A., Artis D. Pathological versus protective functions of IL-22 in airway inflammation are regulated by IL-17A. J Exp Med 2010, 207:1293-1305.
140. Dabrowska M., Skoneczny M., Rode W. Functional gene expression profile underlying methotrexate-induced senescence in human colon cancer cells. Tumour Biol 2011, 32:965-976.
141. Curd L.M., Favors S.E., Gregg R.K. Pro-tumour activity of interleukin-22 in HPAFII human pancreatic cancer cells. Clin Exp Immunol 2012, 168:192-199.
142. Zhang W., Chen Y., Wei H., Zheng C., Sun R., Zhang J., et al. Antiapoptotic activity of autocrine interleukin-22 and therapeutic effects of interleukin-22-small interfering RNA on human lung cancer xenografts. Clin Cancer Res 2008, 14:6432-6439.
143. Feng D., Park O., Radaeva S., Wang H., Yin S., Kong X., et al. Interleukin-22 ameliorates cerulein-induced pancreatitis in mice by inhibiting the autophagic pathway. Int J Biol Sci 2012, 8:249-257.
144. Feng D., Kong X., Weng H., Park O., Wang H., Dooley S., et al. Interleukin-22 promotes proliferation of liver stem/progenitor cells in mice and patients with chronic hepatitis B virus infection. Gastroenterology 2012, 143:188-198. e7.
145. Zhang S., Fujita H., Mitsui H., Yanofsky V.R., Fuentes-Duculan J., Pettersen J.S., et al. Increased Tc22 and Treg/CD8 ratio contribute to aggressive growth of transplant associated squamous cell carcinoma. PLoS ONE 2013, 8:e62154.
146. Zenewicz L.A., Yancopoulos G.D., Valenzuela D.M., Murphy A.J., Karow M., Flavell R.A. Interleukin-22 but not interleukin-17 provides protection to hepatocytes during acute liver inflammation. Immunity 2007, 27:647-659.
147. Pan H., Hong F., Radaeva S., Gao B. Hydrodynamic gene delivery of interleukin-22 protects the mouse liver from concanavalin A-, carbon tetrachloride-, and Fas ligand-induced injury via activation of STAT3. Cell Mol Immunol 2004, 1:43-49.
148. Hoegl S., Bachmann M., Scheiermann P., Goren I., Hofstetter C., Pfeilschifter J., et al. Protective properties of inhaled IL-22 in a model of ventilator-induced lung injury. Am J Respir Cell Mol Biol 2011, 44:369-376.
149. Zenewicz L.A., Yancopoulos G.D., Valenzuela D.M., Murphy A.J., Stevens S., Flavell R.A. Innate and adaptive interleukin-22 protects mice from inflammatory bowel disease. Immunity 2008, 29:947-957.
150. Pociask D.A., Scheller E.V., Mandalapu S., McHugh K.J., Enelow R.I., Fattman C.L., et al. IL-22 is essential for lung epithelial repair following influenza infection. Am J Pathol 2013, 182:1286-1296.
151. Chang Y., Al-Alwan L., Risse P.A., Roussel L., Rousseau S., Halayko A.J., et al. TH17 cytokines induce human airway smooth muscle cell migration. J Allergy Clin Immunol 2011, 127:1046-1053. e1-e2.
152. + T cells in malignant pleural effusion. Cancer Lett 2012, 326:23-32.
153. Kobold S., Volk S., Clauditz T., Kupper N.J., Minner S., Tufman A., et al. Interleukin-22 is frequently expressed in small- and large-cell lung cancer and promotes growth in chemotherapy-resistant cancer cells. J Thorac Oncol 2013, 8:1032-1042.
154. Naher L., Kiyoshima T., Kobayashi I., Wada H., Nagata K., Fujiwara H., et al. STAT3 signal transduction through interleukin-22 in oral squamous cell carcinoma. Int J Oncol 2012, 41:1577-1586.
155. Spehlmann M.E., Manthey C.F., Dann S.M., Hanson E., Sandhu S.S., Liu L.Y., et al. Trp53 deficiency protects against acute intestinal inflammation. J Immunol 2013, 191:837-847.
156. Wen Z., Liao Q., Zhao J., Hu Y., You L., Lu Z., et al. High expression of interleukin-22 and its receptor predicts poor prognosis in pancreatic ductal adenocarcinoma. Ann Surg Oncol 2014, 21:125-132.
157. Ma H.L., Liang S., Li J., Napierata L., Brown T., Benoit S., et al. IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation. J Clin Invest 2008, 118:597-607.
158. Boniface K., Guignouard E., Pedretti N., Garcia M., Delwail A., Bernard F.X., et al. A role for T cell-derived interleukin 22 in psoriatic skin inflammation. Clin Exp Immunol 2007, 150:407-415.
159. Nestle F.O., Kaplan D.H., Barker J. Psoriasis. N Engl J Med 2009, 361:496-509.
160. Armstrong A.W., Voyles S.V., Armstrong E.J., Fuller E.N., Rutledge J.C. Angiogenesis and oxidative stress: common mechanisms linking psoriasis with atherosclerosis. J Dermatol Sci 2011, 63:1-9.
161. Jiang R., Wang H., Deng L., Hou J., Shi R., Yao M., et al. IL-22 is related to development of human colon cancer by activation of STAT3. BMC Cancer 2013, 13:59.
162. Hall M.A., Robinson H., Chan W., Sevick-Muraca E.M. Detection of lymphangiogenesis by near-infrared fluorescence imaging and responses to VEGF-C during healing in a mouse full-dermis thickness wound model. Wound Repair Regen 2013, 21:604-615.
163. Xiang X., Gui H., King N.J., Cole L., Wang H., Xie Q., et al. IL-22 and non-ELR-CXC chemokine expression in chronic hepatitis B virus-infected liver. Immunol Cell Biol 2012, 90:611-619.
164. Zhang Y., Cobleigh M.A., Lian J.Q., Huang C.X., Booth C.J., Bai X.F., et al. A proinflammatory role for interleukin-22 in the immune response to hepatitis B virus. Gastroenterology 2011, 141:1897-1906.
165. Dambacher J., Beigel F., Zitzmann K., Heeg M.H., Goke B., Diepolder H.M., et al. The role of interleukin-22 in hepatitis C virus infection. Cytokine 2008, 41:209-216.
166. Li J., Qiu S.J., She W.M., Wang F.P., Gao H., Li L., et al. Significance of the balance between regulatory T (Treg) and T helper 17 (Th17) cells during hepatitis B virus related liver fibrosis. PLoS ONE 2012, 7:e39307.
167. Okuhara S., Umemura T., Joshita S., Shibata S., Kimura T., Morita S., et al. Serum levels of interleukin-22 and hepatitis B core-related antigen are associated with treatment response to entecavir therapy in chronic hepatitis B. Hepatol Res 2013, 10.1111/hepr.12287.
168. Sousa G.M., Oliveira I.S., Andrade L.J., Sousa-Atta M.L., Parana R., Atta A.M. Serum levels of Th17 associated cytokines in chronic hepatitis C virus infection. Cytokine 2012, 60:138-142.
169. Cusick M.F., Libbey J.E., Fujinami R.S., Eckels D.D. In vitro antigen-specific induction of IL-22 in human subjects that resolved HCV infection. Future Virol 2012, 7:719-728.
170. Waidmann O., Kronenberger B., Scheiermann P., Koberle V., Muhl H., Piiper A. Interleukin 22 serum levels are a negative prognostic indicator in patients with hepatocellular carcinoma. Hepatology 2013, 59:1207.
171. Jiang R., Zhang C., Xia Y., Qian X., Wang X., Sun B. Serum interleukin-22 level is a negative prognostic indicator in patients with HBV-related hepatocellular carcinoma. Hepatology 2013, 59:1208.
172. Park O., Wang H., Weng H., Feigenbaum L., Li H., Yin S., et al. In vivo consequences of liver-specific interleukin-22 expression in mice: implications for human liver disease progression. Hepatology 2011, 54:252-261.
173. Foster R.G., Golden-Mason L., Rutebemberwa A., Rosen H.R. Interleukin (IL)-17/IL-22-producing T cells enriched within the liver of patients with chronic hepatitis C viral (HCV) infection. Dig Dis Sci 2012, 57:381-389.
174. Zhao J., Zhang Z., Luan Y., Zou Z., Sun Y., Li Y., et al. Pathological functions of interleukin-22 in chronic liver inflammation and fibrosis with hepatitis B virus infection by promoting T helper 17 cell recruitment. Hepatology 2014, 59:1331-1342.
175. Ganem D. KSHV infection and the pathogenesis of Kaposi's sarcoma. Annu Rev Pathol 2006, 1:273-296.
176. Johnson J.R., Nishioka M., Chakir J., Risse P.A., Almaghlouth I., Bazarbashi A.N., et al. IL-22 contributes to TGF-beta1-mediated epithelial-mesenchymal transition in asthmatic bronchial epithelial cells. Respir Res 2013, 14:118.
177. Liang M., Wang J., Chu H., Zhu X., He H., Liu Q., et al. Interleukin-22 inhibits bleomycin-induced pulmonary fibrosis. Mediators Inflamm 2013, 2013:209179.
178. Armitage A.E., Eddowes L.A., Gileadi U., Cole S., Spottiswoode N., Selvakumar T.A., et al. Hepcidin regulation by innate immune and infectious stimuli. Blood 2011, 118:4129-4139.
179. Smith C.L., Arvedson T.L., Cooke K.S., Dickmann L.J., Forte C., Li H., et al. IL-22 regulates iron availability in vivo through the induction of hepcidin. J Immunol 2013, 191:1845-1855.
180. Yang L., Zhang Y., Wang L., Fan F., Zhu L., Li Z., et al. Amelioration of high fat diet induced liver lipogenesis and hepatic steatosis by interleukin-22. J Hepatol 2010, 53:339-347.
181. Zhuang Y., Peng L.S., Zhao Y.L., Shi Y., Mao X.H., Guo G., et al. Increased intratumoral IL-22-producing CD4(+) T cells and Th22 cells correlate with gastric cancer progression and predict poor patient survival. Cancer Immunol Immunother 2012, 61:1965-1975.
182. Liu T., Peng L., Yu P., Zhao Y., Shi Y., Mao X., et al. Increased circulating Th22 and Th17 cells are associated with tumor progression and patient survival in human gastric cancer. J Clin Immunol 2012, 32:1332-1339.
183. Vauhkonen H., Vauhkonen M., Sajantila A., Sipponen P., Knuutila S. Characterizing genetically stable and unstable gastric cancers by microsatellites and array comparative genomic hybridization. Cancer Genet Cytogenet 2006, 170:133-139.
184. Petanidis S., Anestakis D., Argyraki M., Hadzopoulou-Cladaras M., Salifoglou A. Differential expression of IL-17, 22 and 23 in the progression of colorectal cancer in patients with K-ras mutation: Ras signal inhibition and crosstalk with GM-CSF and IFN-gamma. PLoS ONE 2013, 8:e73616.
185. Wu T., Cui L., Liang Z., Liu C., Liu Y., Li J. Elevated serum IL-22 levels correlate with chemoresistant condition of colorectal cancer. Clin Immunol 2013, 147:38-39.
186. Nagakawa H., Shimozato O., Yu L., Takiguchi Y., Tatsumi K., Kuriyama T., et al. Expression of interleukin-22 in murine carcinoma cells did not influence tumour growth in vivo but did improve survival of the inoculated hosts. Scand J Immunol 2004, 60:449-454.
187. + T cells correlate with pancreatic cancer progression. Pancreas 2014, 43:470-477.
188. Crnogorac-Jurcevic T., Chelala C., Barry S., Harada T., Bhakta V., Lattimore S., et al. Molecular analysis of precursor lesions in familial pancreatic cancer. PLoS ONE 2013, 8:e54830.
189. Hidalgo M. Pancreatic cancer. N Engl J Med 2010, 362:1605-1617.
190. Vincent A., Herman J., Schulick R., Hruban R.H., Goggins M. Pancreatic cancer. Lancet 2011, 378:607-620.
191. Roman E., Meza-Zepeda L.A., Kresse S.H., Myklebost O., Vasstrand E.N., Ibrahim S.O. Chromosomal aberrations in head and neck squamous cell carcinomas in Norwegian and Sudanese populations by array comparative genomic hybridization. Oncol Rep 2008, 20:825-843.
192. + T cells in hepatocellular carcinoma patients. J Immunol 2010, 185:1544-1549.
193. Kim M.J., Jang J.W., Oh B.S., Kwon J.H., Chung K.W., Jung H.S., et al. Change in inflammatory cytokine profiles after transarterial chemotherapy in patients with hepatocellular carcinoma. Cytokine 2013, 64:516-522.
194. Briso E.M., Guinea-Viniegra J., Bakiri L., Rogon Z., Petzelbauer P., Eils R., et al. Inflammation-mediated skin tumorigenesis induced by epidermal c-Fos. Genes Dev 2013, 27:1959-1973.
195. Wolk K., Haugen H.S., Xu W., Witte E., Waggie K., Anderson M., et al. IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-gamma are not. J Mol Med (Berl) 2009, 87:523-536.
196. Cannavo S., Ferrau F., Cotta O.R., Saitta S., Barresi V., Cristani M.T., et al. Increased serum interleukin-22 levels in patients with PRL-secreting and non-functioning pituitary macroadenomas. Pituitary 2013, 17(1):76-80.
197. Ma Y., Aymeric L., Locher C., Mattarollo S.R., Delahaye N.F., Pereira P., et al. Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy. J Exp Med 2011, 208:491-503.
198. Sung C.O., Kim S.C., Karnan S., Karube K., Shin H.J., Nam D.H., et al. Genomic profiling combined with gene expression profiling in primary central nervous system lymphoma. Blood 2011, 117:1291-1300.
199. Matsuyama H., Suzuki H.I., Nishimori H., Noguchi M., Yao T., Komatsu N., et al. miR-135b mediates NPM-ALK-driven oncogenicity and renders IL-17-producing immunophenotype to anaplastic large cell lymphoma. Blood 2011, 118:6881-6892.
200. + subtypes. Blood 2007, 109:2156-2164.
201. Miyagaki T., Sugaya M., Suga H., Kamata M., Ohmatsu H., Fujita H., et al. IL-22, but not IL-17, dominant environment in cutaneous T-cell lymphoma. Clin Cancer Res 2011, 17:7529-7538.
202. Shao L.L., Zhang L., Hou Y., Yu S., Liu X.G., Huang X.Y., et al. Th22 cells as well as Th17 cells expand differentially in patients with early-stage and late-stage myelodysplastic syndrome. PLoS ONE 2012, 7:e51339.
203. Yu S., Liu C., Zhang L., Shan B., Tian T., Hu Y., et al. Elevated Th22 cells correlated with Th17 cells in peripheral blood of patients with acute myeloid leukemia. Int J Mol Sci 2014, 15:1927-1945.
204. Sun Y.X., Kong H.L., Liu C.F., Yu S., Tian T., Ma D.X., et al. The imbalanced profile and clinical significance of T helper associated cytokines in bone marrow microenvironment of the patients with acute myeloid leukemia. Hum Immunol 2013, 75(2):113-118.
205. Tian T., Sun Y., Li M., He N., Yuan C., Yu S., et al. Increased Th22 cells as well as Th17 cells in patients with adult T-cell acute lymphoblastic leukemia. Clin Chim Acta 2013, 426:108-113.
206. Liu L.-M., Zhang X.-X., Zhao G.-S., Si Y.-J., Lin G.-Q., Zhang Y.-M., et al. The significance of change of Th22 cells in patients with acute lymphoblastic leukemia. Chin J Hematol 2012, 33:985-988.
207. Cao Y., Luetkens T., Kobold S., Hildebrandt Y., Gordic M., Lajmi N., et al. The cytokine/chemokine pattern in the bone marrow environment of multiple myeloma patients. Exp Hematol 2010, 38:860-867.
208. Thompson C.L., Plummer S.J., Tucker T.C., Casey G., Li L. Interleukin-22 genetic polymorphisms and risk of colon cancer. Cancer Causes Control 2010, 21:1165-1170.
209. Eun Y.G., Shin I.H., Lee Y.C., Shin S.Y., Kim S.K., Chung J.H., et al. Interleukin 22 polymorphisms and papillary thyroid cancer. J Endocrinol Invest 2013, 36:584-587.
210. Izykowska K., Zawada M., Nowicka K., Grabarczyk P., Braun F.C., Delin M., et al. Identification of multiple complex rearrangements associated with deletions in the 6q23-27 region in Sezary syndrome. J Invest Dermatol 2013, 133:2617-2625.
211. Yao J., Liu L., Yang M. Interleukin-23 receptor genetic variants contribute to susceptibility of multiple cancers. Gene 2014, 533:21-25.
212. Zhou S., Ruan Y., Yu H., Chen Y., Yao Y., Ma Y., et al. Functional IL-23R rs10889677 genetic polymorphism and risk of multiple solid tumors: a meta-analysis. PLoS ONE 2013, 8:e80627.
213. Munoz M., Heimesaat M.M., Danker K., Struck D., Lohmann U., Plickert R., et al. Interleukin (IL)-23 mediates Toxoplasma gondii-induced immunopathology in the gut via matrixmetalloproteinase-2 and IL-22 but independent of IL-17. J Exp Med 2009, 206:3047-3059.
214. Musolino C., Allegra A., Ferraro M., Aguennouz M., Russo S., Alonci A., et al. Involvement of T2677 T multidrug resistance gene polymorphism in Interleukin 22 plasma concentration in B-chronic lymphocytic leukemia patients. Acta Oncol 2012, 51:406-408.
215. Ramesh R., Kozhaya L., McKevitt K., Djuretic I.M., Carlson T.J., Quintero M.A., et al. Pro-inflammatory human Th17 cells selectively express P-glycoprotein and are refractory to glucocorticoids. J Exp Med 2014, 211(1):89-104.
216. Parrish-Novak J., Xu W., Brender T., Yao L., Jones C., West J., et al. Interleukins 19, 20, and 24 signal through two distinct receptor complexes. Differences in receptor-ligand interactions mediate unique biological functions. J Biol Chem 2002, 277:47517-47523.
217. Wang M., Tan Z., Zhang R., Kotenko S.V., Liang P. Interleukin 24 (MDA-7/MOB-5) signals through two heterodimeric receptors, IL-22R1/IL-20R2 and IL-20R1/IL-20R2. J Biol Chem 2002, 277:7341-7347.
218. Wolk K., Witte E., Warszawska K., Schulze-Tanzil G., Witte K., Philipp S., et al. The Th17 cytokine IL-22 induces IL-20 production in keratinocytes: a novel immunological cascade with potential relevance in psoriasis. Eur J Immunol 2009, 39:3570-3581.
219. Jung M.Y., Kim S.H., Cho D., Kim T.S. Analysis of the expression profiles of cytokines and cytokine-related genes during the progression of breast cancer growth in mice. Oncol Rep 2009, 22:1141-1147.
220. Hsu Y.H., Hsing C.H., Li C.F., Chan C.H., Chang M.C., Yan J.J., et al. Anti-IL-20 monoclonal antibody suppresses breast cancer progression and bone osteolysis in murine models. J Immunol 2012, 188:1981-1991.
221. Lee S.J., Cho S.C., Lee E.J., Kim S., Lee S.B., Lim J.H., et al. Interleukin-20 promotes migration of bladder cancer cells through extracellular signal-regulated kinase (ERK)-mediated MMP-9 protein expression leading to nuclear factor (NF-kappaB) activation by inducing the up-regulation of p21(WAF1) protein expression. J Biol Chem 2013, 288:5539-5552.
222. Heuze-Vourc'h N., Liu M., Dalwadi H., Baratelli F.E., Zhu L., Goodglick L., et al. IL-20, an anti-angiogenic cytokine that inhibits COX-2 expression. Biochem Biophys Res Commun 2005, 333:470-475.
223. Hsieh M.Y., Chen W.Y., Jiang M.J., Cheng B.C., Huang T.Y., Chang M.S. Interleukin-20 promotes angiogenesis in a direct and indirect manner. Genes Immun 2006, 7:234-242.
224. Ramesh R., Mhashilkar A.M., Tanaka F., Saito Y., Branch C.D., Sieger K., et al. Melanoma differentiation-associated gene 7/interleukin (IL)-24 is a novel ligand that regulates angiogenesis via the IL-22 receptor. Cancer Res 2003, 63:5105-5113.
225. Jiang H., Lin J.J., Su Z.Z., Goldstein N.I., Fisher P.B. Subtraction hybridization identifies a novel melanoma differentiation associated gene, mda-7, modulated during human melanoma differentiation, growth and progression. Oncogene 1995, 11:2477-2486.
226. Poindexter N.J., Walch E.T., Chada S., Grimm E.A. Cytokine induction of interleukin-24 in human peripheral blood mononuclear cells. J Leukoc Biol 2005, 78:745-752.
227. Garn H., Schmidt A., Grau V., Stumpf S., Kaufmann A., Becker M., et al. IL-24 is expressed by rat and human macrophages. Immunobiology 2002, 205:321-334.
228. Caudell E.G., Mumm J.B., Poindexter N., Ekmekcioglu S., Mhashilkar A.M., Yang X.H., et al. The protein product of the tumor suppressor gene, melanoma differentiation-associated gene 7, exhibits immunostimulatory activity and is designated IL-24. J Immunol 2002, 168:6041-6046.
229. Mumm J.B., Ekmekcioglu S., Poindexter N.J., Chada S., Grimm E.A. Soluble human MDA-7/IL-24: characterization of the molecular form(s) inhibiting tumor growth and stimulating monocytes. J Interferon Cytokine Res 2006, 26:877-886.
230. Saito Y., Miyahara R., Gopalan B., Litvak A., Inoue S., Shanker M., et al. Selective induction of cell cycle arrest and apoptosis in human prostate cancer cells through adenoviral transfer of the melanoma differentiation-associated-7 (mda-7)/interleukin-24 (IL-24) gene. Cancer Gene Ther 2005, 12:238-247.
231. Gopalan B., Shanker M., Chada S., Ramesh R. MDA-7/IL-24 suppresses human ovarian carcinoma growth in vitro and in vivo. Mol Cancer 2007, 6:11.
232. Gopalan B., Litvak A., Sharma S., Mhashilkar A.M., Chada S., Ramesh R. Activation of the Fas-FasL signaling pathway by MDA-7/IL-24 kills human ovarian cancer cells. Cancer Res 2005, 65:3017-3024.
233. Yacoub A., Mitchell C., Hong Y., Gopalkrishnan R.V., Su Z.Z., Gupta P., et al. MDA-7 regulates cell growth and radiosensitivity in vitro of primary (non-established) human glioma cells. Cancer Biol Ther 2004, 3:739-751.
234. Lebedeva I.V., Su Z.Z., Sarkar D., Kitada S., Dent P., Waxman S., et al. Melanoma differentiation associated gene-7, mda-7/interleukin-24, induces apoptosis in prostate cancer cells by promoting mitochondrial dysfunction and inducing reactive oxygen species. Cancer Res 2003, 63:8138-8144.
235. Yacoub A., Park M.A., Gupta P., Rahmani M., Zhang G., Hamed H., et al. Caspase-, cathepsin-, and PERK-dependent regulation of MDA-7/IL-24-induced cell killing in primary human glioma cells. Mol Cancer Ther 2008, 7:297-313.
236. Chen W.Y., Cheng Y.T., Lei H.Y., Chang C.P., Wang C.W., Chang M.S. IL-24 inhibits the growth of hepatoma cells in vivo. Genes Immun 2005, 6:493-499.
237. Xie Y., Sheng W., Xiang J., Ye Z., Zhu Y., Chen X., et al. Recombinant human IL-24 suppresses lung carcinoma cell growth via induction of cell apoptosis and inhibition of tumor angiogenesis. Cancer Biother Radiopharm 2008, 23:310-320.
238. Fisher P.B., Sarkar D., Lebedeva I.V., Emdad L., Gupta P., Sauane M., et al. Melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24): novel gene therapeutic for metastatic melanoma. Toxicol Appl Pharmacol 2007, 224:300-307.
239. Sieger K.A., Mhashilkar A.M., Stewart A., Sutton R.B., Strube R.W., Chen S.Y., et al. The tumor suppressor activity of MDA-7/IL-24 is mediated by intracellular protein expression in NSCLC cells. Mol Ther 2004, 9:355-367.
240. Sauane M., Lebedeva I.V., Su Z.Z., Choo H.T., Randolph A., Valerie K., et al. Melanoma differentiation associated gene-7/interleukin-24 promotes tumor cell-specific apoptosis through both secretory and nonsecretory pathways. Cancer Res 2004, 64:2988-2993.
241. Ishikawa S., Nakagawa T., Miyahara R., Kawano Y., Takenaka K., Yanagihara K., et al. Expression of MDA-7/IL-24 and its clinical significance in resected non-small cell lung cancer. Clin Cancer Res 2005, 11:1198-1202.
242. Ellerhorst J.A., Prieto V.G., Ekmekcioglu S., Broemeling L., Yekell S., Chada S., et al. Loss of MDA-7 expression with progression of melanoma. J Clin Oncol 2002, 20:1069-1074.
243. Eager R., Harle L. Nemunaitis J. Ad-MDA-7; INGN 241: a review of preclinical and clinical experience. Expert Opin Biol Ther 2008, 8:1633-1643.
244. Dent P., Yacoub A., Hamed H.A., Park M.A., Dash R., Bhutia S.K., et al. The development of MDA-7/IL-24 as a cancer therapeutic. Pharmacol Ther 2010, 128:375-384.
245. Cunningham C.C., Chada S., Merritt J.A., Tong A., Senzer N., Zhang Y., et al. Clinical and local biological effects of an intratumoral injection of mda-7 (IL24; INGN 241) in patients with advanced carcinoma: a phase I study. Mol Ther 2005, 11:149-159.
246. Tong A.W., Nemunaitis J., Su D., Zhang Y., Cunningham C., Senzer N., et al. Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/IL24): biologic outcome in advanced cancer patients. Mol Ther 2005, 11:160-172.
247. Feng D. Interleukin-22, liver progenitor cells, and liver cancer. Hepatology 2013, 10.1002/hep.26899.
248. Caproni M., Antiga E., Melani L., Volpi W., Del Bianco E., Fabbri P. Serum levels of IL-17 and IL-22 are reduced by etanercept, but not by acitretin, in patients with psoriasis: a randomized-controlled trial. J Clin Immunol 2009, 29:210-214.
249. Furqan M., Akinleye A., Mukhi N., Mittal V., Chen Y., Liu D. STAT inhibitors for cancer therapy. J Hematol Oncol 2013, 6:90.
250. Fagard R., Metelev V., Souissi I., Baran-Marszak F. STAT3 inhibitors for cancer therapy: have all roads been explored?. JAKSTAT 2013, 2:e22882.